After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.

The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.Final results of the randomized ...

Nivolumab plus ipilimumab was also associated with a significant improvement in the median duration of response (30.4 months [95% CI, 21.2-not evaluable] vs 12.9 months ...

Median PFS with nivolumab + ipilimumab vs nivolumab monotherapy was not reached vs 39.3 months, respectively (HR, 0.62), and the overall response rates were 71% and 58%, respectively.

First-line nivolumab plus ipilimumab significantly extended OS compared with platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma, according to results of an ...

The median overall survival (OS) was 52.7 months with nivolumab-ipilimumab and 37.8 months with sunitinib (HR, 0.72; 95% CI 0.62-0.83). The estimated 90-month OS rates were 35.1% and 24.9% ...

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

In the phase I or II CheckMate 032 trial, clinical activity with nivolumab and nivolumab plus ipilimumab was observed for relapsed SCLC. 11-13 However, nivolumab did not improve survival over ...

The sBLA was based on data from the open-label, multicenter, randomized phase 3 CheckMate -9LA trial that compared the efficacy of nivolumab plus ipilimumab in combination with chemotherapy to ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Yao T, Kang YK, Kim TU, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in few responses among patients who did not achieve a response with nivolumab alone, according to ...